Dimensional Fund Advisors LP Has $1.89 Million Holdings in Aura Biosciences, Inc. (NASDAQ:AURA)

Dimensional Fund Advisors LP grew its holdings in Aura Biosciences, Inc. (NASDAQ:AURA) by 20.0% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 250,375 shares of the company’s stock after purchasing an additional 41,711 shares during the period. Dimensional Fund Advisors LP owned about 0.51% of Aura Biosciences worth $1,892,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. American Century Companies Inc. purchased a new position in Aura Biosciences during the second quarter valued at approximately $119,000. American International Group Inc. increased its stake in shares of Aura Biosciences by 27.4% in the first quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after acquiring an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Aura Biosciences during the first quarter worth $144,000. Rhumbline Advisers boosted its position in Aura Biosciences by 39.6% during the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock valued at $480,000 after purchasing an additional 18,011 shares during the last quarter. Finally, Levin Capital Strategies L.P. grew its stake in Aura Biosciences by 11.2% in the first quarter. Levin Capital Strategies L.P. now owns 111,200 shares of the company’s stock valued at $873,000 after purchasing an additional 11,200 shares in the last quarter. 96.75% of the stock is owned by hedge funds and other institutional investors.

Aura Biosciences Stock Performance

Shares of NASDAQ AURA opened at $9.08 on Friday. The firm has a market cap of $449.85 million, a price-to-earnings ratio of -4.88 and a beta of 0.37. The business’s 50-day simple moving average is $8.48 and its 200-day simple moving average is $7.97. Aura Biosciences, Inc. has a 52 week low of $5.99 and a 52 week high of $12.35.

Aura Biosciences (NASDAQ:AURA) last issued its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) EPS for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.04. As a group, equities research analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have weighed in on AURA shares. JMP Securities upped their target price on Aura Biosciences from $19.00 to $23.00 and gave the stock a “market outperform” rating in a research report on Friday, September 13th. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 9th. HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of Aura Biosciences in a research report on Friday, September 13th. Finally, Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research report on Monday, September 16th. Three analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat, Aura Biosciences presently has a consensus rating of “Buy” and an average price target of $21.67.

Aura Biosciences Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.